TD Cowen: 'Ultragenyx Pharma (RARE) a Buying Oppy Ahead Of Dec '25 Readout'

TD Cowen analyst Yaron Werber reiterated a Buy rating and $86.00 price target on Ultragenyx Pharma (NASDAQ: RARE).

The analyst commented: "IA2 Miss Disappointing But RARE A Buying Oppy Ahead Of Dec '25 Final Readout; Lack of IA2 hit disappointing but we reiterate conviction in setrusumab's efficacy; KOL optimism predicts strong uptake in any case on AFR reduction of >20-25% if Orbit succeeds. Our analyses estimate >70% chance of success at final analysis at >40% tx effect. We view weakness (stock trading at $29/sh post-close) as buying oppy ahead of final analysis (Dec '25) given our conviction in success."

For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.

Shares of Ultragenyx Pharma closed at $41.44 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Critical One Energy closes second tranche of flow-through placement
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy